Lung Diseases Cies Search Engine [selected websites]

Showing posts with label Novelos. Show all posts
Showing posts with label Novelos. Show all posts

Mar 14, 2008

Novelos Therapeutics, Pivotal Phase 3 Lung Cancer Trial

March 13, 2008 - -Novelos Therapeutics, Inc. (OTCBB: NVLT), a biopharmaceutical company focused on the development of therapeutics to treat cancer and hepatitis, today announced that Novelos has reached the target enrollment of 840 patients in the pivotal Phase 3 trial in advanced non-small cell lung cancer (NSCLC) for its lead product NOV-002 in combination with first-line chemotherapy... [PDF] Novelos' Press Release -

Oct 2, 2007

development of NOV-002, Novelos' lead compound in pivotal Phase 3 trial for non-small cell lung cancer

October 1, 2007 - Novelos Therapeutics, Inc. (OTCBB: NVLT), a biopharmaceutical company focused on the development of therapeutics to treat cancer and hepatitis, announced that Novelos, in collaboration with the Medical University of South Carolina (MUSC), was awarded a $150,000 competitive grant by the National Institutes of Health (NIH) under Phase I of the Small Business Technology Transfer (STTR) program. This grant will support further scientific development of NOV-002, Novelos' lead compound in pivotal Phase 3 trial for non-small cell lung cancer under a Special Protocol Assessment (SPA) and Fast Track... Novelos' Press Release [PDF] -

Sep 11, 2007

Novelos Therapeutics, 5th U.S. Patent

Monday September 10, 2007 - Novelos Therapeutics, Inc. (OTCBB: NVLT), a biopharmaceutical company focused on the development of therapeutics to treat cancer and hepatitis, announced that Novelos was issued U.S. Pat. No. 7,169,412 by the U.S. Patent and Trademark Office extending the composition and method of use claims relating to NOV-002, Novelos' lead compound in pivotal Phase 3 trial for non-small cell lung cancer under a Special Protocol Assessment (SPA) and Fast Track... Novelos Therapeutics' Press Release -